Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

27.12 -0.79 (-2.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
From Castle Biosciences, Inc.
Via Business Wire
News headline image
DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence
From Castle Biosciences, Inc.
Via Business Wire
News headline image
New Data Demonstrating Accuracy of DecisionDx® DiffDx™-Melanoma Presented at ASDP 58th Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Acquire Cernostics
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences's Return On Capital Employed Overview ↗
Castle Biosciences (NASDAQ:CSTL) brought in sales totaling $22.76 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 105.65%, resulting in a... 
Via Benzinga
News headline image
Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma
From Castle Biosciences
Via Business Wire
News headline image
Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
News headline image
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Q2 Earnings Edges Out Expectation On Record Test Report Volume ↗
After the market close on Monday, Castle Biosciences Inc (NASDAQ: CSTL) reported that its second-quarter revenues rose 79% Y/Y to $22.75 million, beating the... 
Via Benzinga
News headline image
Castle Biosciences Announces Second Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the DERM2021 NP/PA CME Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Collaborates with the Melanoma Research Foundation
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Participate at the Canaccord Genuity 41st Annual Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck
From Castle Biosciences, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
News headline image
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Expands its Board of Directors with New Appointments
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Return On Capital Employed Overview: Castle Biosciences ↗
In Q1, Castle Biosciences (NASDAQ:CSTL) posted sales of $22.81 million. Earnings were up 41.29%, but Castle Biosciences still reported an overall loss of $4.28 million. Castle... 
Via Benzinga
News headline image
Castle Biosciences is Listed in the Houston Chronicle’s “CHRON 100” as One of the 100 Most Successful Publicly Traded Companies in Houston
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Receipt of New York Laboratory Permit
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Looking Into Castle Biosciences's Return On Capital Employed ↗
During Q1, Castle Biosciences's (NASDAQ:CSTL) reported sales totaled $22.81 million. Despite a 41.29% in earnings, the company posted a loss of $4.28 million. Castle Biosciences... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.